Biomarker-matched drug combos shrink treatment-resistant melanoma in preclinical models

Medical Xpress

Biomarker-matched drug combos shrink treatment-resistant melanoma in preclinical models

이 뉴스, 어떠셨어요?

한 번의 탭으로 반응을 남겨요 · 로그인 불필요

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to tailor drug combinations based on specific tumor biology to improve outcomes for treatment-resistant advanced melanoma. ...

전문 보기

Biomarker-matched drug combos shrink treatment-resistant melanoma in preclinical models

이 뉴스, 어떠셨어요?

관련 뉴스

'science' 카테고리 뉴스

Purine-heavy DNA sequences protect Bacillus subtilis genes from Rho termination

Brown leaves before fall could signal lasting heat damage, researchers warn

FDA approves Tzield for children with new stage 3 type 1 diabetes

Medical Xpress의 다른 기사

Bofanglutide linked to meaningful reductions in HbA1c in adults with T2DM

New drug unlocks elusive immune receptor, opening path toward motor neuron disease treatments

EHA: Adding Pirtobrutinib to Venetoclax-Rituximab ups progression-free survival in chronic lymphocytic leukemia